Want to see AU:IMM full AI Analyst Report?

Immutep Ltd (IMM) Price & Analysis

156 Followers

IMM Stock Chart & Stats

AU$0.05

AU$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

AU$0.05

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.47

Previous CloseN/A

Volume4.97M

Average Volume (3M)14.73M

Market Cap

AU$33.90M

Enterprise ValueAU$10.28M

Total Cash (Recent Filing)AU$68.87M

Total Debt (Recent Filing)AU$1.05M

Price to Earnings (P/E)―

Beta1.87

Next Earnings

Feb 25, 2027

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding1,474,110,200

10 Day Avg. Volume10,632,859

30 Day Avg. Volume14,729,318

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)1.27

Price to Sales (P/S)5.36

P/FCF Ratio-1.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.07

Price Target Upside40.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.01

Revenue Forecast (FY)AU$3.85M

Bulls Say, Bears Say

Bulls Say

Revenue And Gross Margin ImprovementThe sharp FY2026 improvement in revenue and gross margin indicates stronger commercial or partner-related traction and better economics than earlier periods. If maintained, this combination can expand resources available for development and improve the company’s path toward sustainable operating leverage.

Low Financial LeverageVery low debt limits interest burden and reduces balance-sheet risk compared with a highly leveraged biotechnology company. The remaining equity capital provides some financial buffer, preserving flexibility to fund operations and clinical development without substantial debt-servicing pressure.

Focused LAG-3 Immunotherapy PlatformA focused LAG-3 platform gives Immutep a consistent scientific foundation across immuno-oncology and immunotherapy programs. Clinical evaluation and industry collaboration may support development leverage, broaden potential applications, and create several routes to future partner-related revenue.

Bears Say

Persistent Large Net LossesThe substantial net loss shows that improved revenue has not yet translated into financial sustainability. Continued operating expense intensity can absorb future revenue gains, limit internally funded development, and keep the company dependent on external capital while programs remain in development.

Material Cash BurnMeaningfully negative operating and free cash flow indicate that the business consumes cash rather than funding itself. Persistent burn can restrict clinical investment, reduce financial flexibility, and require additional external funding until operating scale or product-related receipts improve.

Eroding Equity And Funding RiskThe steep reduction in equity reflects the financial impact of ongoing losses and increases reliance on future financing. If losses persist, additional capital may be required to sustain operations, creating funding and potential dilution risk despite the company’s low debt.

Immutep Ltd News

Immutep, Monash University secure further ARC linkage projects

Immutep (IMMP) announced that the Australian Research Council, or ARC, has awarded Monash University a grant of A$652,248...

4d ago

IMMP

Immutep regains compliance with Nasdaq minimum bid price requirement

Immutep (IMMP) announced that it has received written notification from the Listing Qualifications Department of Nasdaq confirming that...

5d ago

IMMP

Immutep receives A$856,669 cash rebate from Australia R&D tax incentive program

Immutep (IMMP) announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive...

18d ago

IMMP

Immutep Ltd trading halted, news pending

19:50 EDT Immutep (IMMP) Ltd trading halted, news pending Published first on TheFly – the ultimate source for...

22d ago

IMMP

Immutep, Monash Win New ARC Grant to Advance LAG-3 Research

Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep Limited has secured further support for its long-running...

4d ago

Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change

Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Ltd has regained compliance with Nasdaq’s minimum bid...

5d ago

Immutep Moves to Restore ASX Audit Committee Compliance After Director Exit

An update from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep has disclosed that its Audit and...

9d ago

Immutep Details Equity Interests of Departing Director Pete Meyers

Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep Ltd has disclosed a final director’s interest notice...

13d ago

Immutep Reports Lapse of 2 Million Performance Rights

Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Limited has notified the market that 2,058,631 performance...

13d ago

Immutep Announces Board Resignation and Search for New Non-Executive Director

Immutep Ltd ( ($AU:IMM) ) has shared an update. Immutep Limited has announced the resignation of Non-Executive Director...

13d ago

Immutep Director Increases Shareholding Through Performance Rights Exercise

Immutep Ltd ( ($AU:IMM) ) has provided an announcement. Immutep Ltd has reported a change in director Pete...

17d ago

Immutep Applies to Quote New Ordinary Shares on ASX

Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Limited has applied for the quotation of 388,889...

17d ago

Immutep boosts R&D funding with multi-jurisdiction tax incentives

The latest update is out from Immutep Ltd ( ($AU:IMM) ). Immutep has received an A$856,669 cash rebate...

18d ago

Immutep Adjusts ADS Ratio to Safeguard Nasdaq Listing

Immutep Ltd ( ($AU:IMM) ) has provided an announcement. Immutep has announced a significant change to the ratio...

27d ago

IMM FAQ

What was Immutep Ltd’s price range in the past 12 months?

Immutep Ltd lowest share price was AU$0.02 and its highest was AU$0.47 in the past 12 months.

What is Immutep Ltd’s market cap?

Immutep Ltd’s market cap is AU$33.90M.

When is Immutep Ltd’s upcoming earnings report date?

Immutep Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 130 days.

How were Immutep Ltd’s earnings last quarter?

Immutep Ltd released its earnings results on Sep 02, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of -AU$0.004 by -AU$0.019.

Is Immutep Ltd overvalued?

According to Wall Street analysts Immutep Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immutep Ltd pay dividends?

Immutep Ltd does not currently pay dividends.

What is Immutep Ltd’s EPS estimate?

Immutep Ltd’s EPS estimate is -0.01.

How many shares outstanding does Immutep Ltd have?

Immutep Ltd has 1,474,110,200 shares outstanding.

What happened to Immutep Ltd’s price movement after its last earnings report?

Immutep Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of -AU$0.004. Following the earnings report the stock price went down -3.922%.

Which hedge fund is a major shareholder of Immutep Ltd?

Currently, no hedge funds are holding shares in AU:IMM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Immutep Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-98.86%

Trailing 12-Months

Asset Growth

-43.93%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Immutep Ltd

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Ltd (IMM) Earnings & Revenues

Historic Earnings Reports

IMM Stock 12 Month Forecast

Average Price Target

AU$0.07

▲(40.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.033,0.03661538461538462,0.04023076923076923,0.04384615384615385,0.047461538461538465,0.051076923076923075,0.05469230769230769,0.05830769230769231,0.06192307692307693,0.06553846153846155,0.06915384615384615,0.07276923076923078,0.07638461538461538,{"y":0.08,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.033,0.03584615384615385,0.03869230769230769,0.04153846153846154,0.044384615384615383,0.04723076923076923,0.05007692307692308,0.05292307692307693,0.05576923076923077,0.05861538461538462,0.06146153846153846,0.06430769230769232,0.06715384615384616,{"y":0.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.033,0.035076923076923075,0.037153846153846155,0.03923076923076923,0.04130769230769231,0.04338461538461538,0.045461538461538456,0.047538461538461536,0.04961538461538462,0.05169230769230769,0.053769230769230764,0.055846153846153844,0.05792307692307692,{"y":0.06,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.295,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.415,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.405,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.385,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.046,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.061,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.053,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.057,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.046,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.051,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.033,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >